Short Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expands By 86.3%

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 742,800 shares, a growth of 86.3% from the February 13th total of 398,700 shares. Approximately 1.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 817,700 shares, the days-to-cover ratio is presently 0.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a research report on Friday, February 28th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of large investors have recently modified their holdings of MIST. Atria Investments Inc boosted its holdings in shares of Milestone Pharmaceuticals by 44.4% in the 3rd quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares in the last quarter. PVG Asset Management Corp acquired a new stake in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $46,000. Jones Financial Companies Lllp boosted its holdings in shares of Milestone Pharmaceuticals by 1,000.0% in the 4th quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Milestone Pharmaceuticals in the 4th quarter valued at $170,000. Finally, National Bank of Canada FI boosted its holdings in shares of Milestone Pharmaceuticals by 163.4% in the 4th quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock traded up $0.14 during trading hours on Friday, reaching $2.17. The company’s stock had a trading volume of 2,438,222 shares, compared to its average volume of 388,516. The firm’s 50 day simple moving average is $2.02 and its 200-day simple moving average is $1.79. The company has a market capitalization of $115.72 million, a price-to-earnings ratio of -2.68 and a beta of 1.83. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.